Webinar: Palbociclib (Ibrance) for metastatic ER+ breast cancer - NZ update
Monday March 19
Palbociclib (brand name Ibrance) is a new medicine for advanced ER+ breast cancer that has achieved significant results in high-profile clinical trials overseas. It's not funded in New Zealand, but some Kiwis have been buying it off-shore, and there will soon be compassionate access for NZ patients that will make it potentially more affordable.
Meet your panel:
Dr Richard Finn is associate professor of Medicine at the UCLA David Geffen School of Medicine. He led the PALOMA series of clinical trials for palbociclib and is considered one of the world's foremost experts on this new drug.